| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MPL; MPLV; TPOR; C-MPL; THCYT2 |
| Entrez GeneID | 4352 |
| clone | 1D6B7 |
| WB Predicted band size | 71.2kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD110 (AA: extra 26-175) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CD110(TPO-R)抗体相关的文献摘要整理：
1. **《Targeting CD110/TPO-R on acute myeloid leukemia cells as a novel immunotherapy》**
- 作者：Smith A, et al. (2022)
- 摘要：研究开发了一种靶向CD110的单克隆抗体，通过阻断TPO信号通路抑制急性髓系白血病(AML)细胞增殖，并在小鼠模型中显著减少肿瘤负荷。
2. **《CD110 promotes a cancer stem cell phenotype in breast cancer》**
- 作者：Zhang L, et al. (2020)
- 摘要：利用CD110抗体阻断实验，发现CD110通过激活STAT3通路增强乳腺癌干细胞的自我更新能力，提示其作为治疗三阴性乳腺癌的潜在靶点。
3. **《A neutralizing anti-CD110 antibody ameliorates thrombocytopenia in a murine model》**
- 作者：Tanaka K, et al. (2019)
- 摘要：开发了一种中和性CD110抗体，可有效恢复免疫性血小板减少症(ITP)模型小鼠的血小板水平，证明其治疗血小板相关疾病的潜力。
4. **《CD110 expression correlates with JAK2-V617F mutation in myeloproliferative neoplasms》**
- 作者：Chen H, et al. (2018)
- 摘要：通过CD110抗体流式分析，发现骨髓增殖性肿瘤患者中CD110高表达与JAK2突变相关，为疾病诊断和靶向治疗提供依据。
(注：以上文献为示例，实际引用需核对真实出版物信息。)
CD110. also known as the thrombopoietin receptor (TPO-R) or MPL, is a cytokine receptor encoded by the *MPL* gene. It belongs to the type I hematopoietic cytokine receptor family and plays a critical role in regulating megakaryocyte development, platelet production, and hematopoietic stem cell maintenance. Thrombopoietin (TPO), its ligand, binds to CD110 to activate downstream signaling pathways like JAK-STAT, PI3K/AKT, and MAPK, promoting cell survival, proliferation, and differentiation. Dysregulation of CD110 signaling is implicated in blood disorders, including thrombocytopenia, myeloproliferative neoplasms (MPNs), and leukemia.
CD110 antibodies are essential tools for studying receptor expression, activation mechanisms, and TPO/MPL interactions. In research, they are used in flow cytometry, Western blotting, and immunohistochemistry to detect CD110 in hematopoietic tissues or cell lines. Therapeutically, CD110 is a target for treating thrombocytopenia. Drugs like romiplostim (a TPO mimetic) and eltrombopag (a non-peptide TPO-R agonist) mimic TPO to stimulate platelet production, while inhibitory antibodies or small molecules are explored for MPNs associated with hyperactive CD110 signaling, such as myelofibrosis.
Mutations in *MPL* (e.g., MPL W515L) are linked to aberrant signaling and disease progression, making CD110 antibodies valuable in diagnostic panels. Ongoing research focuses on optimizing antibody specificity and developing bispecific antibodies for targeted therapies. Overall, CD110 antibodies bridge basic research and clinical applications in hematology.
×
